Loading…
← CockpitCompetitor Analysis › MARKSANS.NS Marksans Pharma LimitedOpen in the cockpit ↗

Marksans Pharma LimitedMARKSANS.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Manufactures generic formulations exported to the US, UK and Australia through owned subsidiaries.

≈ A generics manufacturer exporting via owned distribution subsidiariesMomentum strong 69
Mkt cap
$1.43B
US dollars, full cap
Free float
47%
of shares outstanding
$/day
$4.88M
20-day average traded
Fwd P/E
23.2×
forward earnings
ROIC−WACC
-0.5 pp
WACC 19.0%
Hurdle
+14 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · INR₹294.50
1D-3.8%
1W-3.9%
1M-2.8%
3M-9.8%
6M+35.5%
YTD+63.4%
1Y+49.5%
ATR %4.4%
Beta0.92
52w lowhigh16.1% off high

What Marksans Pharma does

Manufactures generic formulations exported to the US, UK and Australia through owned subsidiaries.

Makes the drugs in its own plants and sells them through its own marketing subsidiaries in each regulated market, so it deals directly with pharmacy chains and distributors rather than through a third-party marketer. India is the production base, and sales are mostly overseas.

In one line: A generics manufacturer exporting via owned distribution subsidiaries.

Products and services

  • US generic formulations
  • UK/Australia generics
  • OTC/nutraceuticals

Customers

  • US/UK/Australia pharmacy distributors

Where it sits in the supply chain

  • Formulation manufacturing
  • Regulatory filings
  • Export via owned subsidiaries (Bell…

What could go right

  • Regulated market generic volume growth
  • New product approvals

What could go wrong

  • US generic price erosion
  • FDA inspection risk

Moat: narrow (regulatory licence). FDA/MHRA-approved plants plus owned marketing subsidiaries in regulated markets support steady exports.

Headquarters: Mumbai, India · Founded: 1982 · Employees: 1,685

Named competitors

Marksans Pharma at a glance

Size Marksans Pharma (MARKSANS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.43B, the 493rd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹294.50 on 18 Nov 2026.

Performance Over six months the shares gained 35.5%, against -14.6% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 20 in its peer set.

Growth Revenue grew 24.2% over the last twelve months (peer median +11.3%); the operating margin is 20.0% (peer median 10.2%).

Valuation It trades at 23.2× forward earnings against a peer median of 16.0× (5th most expensive of 10).

Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.5 points below its cost of capital (19.0% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026MARKSANS.NS 135Peer median 88
Six months, rebased to 100: Marksans Pharma against the median of its 20 peers (local-currency closes).

Marksans Pharma financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹33.9B₹29.5B₹26.2B₹21.8B₹18.5B
Revenue growth—+13%+20%+18%—
Gross profit₹13.9B₹9.45B₹8.65B₹7.02B₹5.96B
EBITDA₹7.83B₹6.00B₹5.30B₹4.61B₹3.52B
Net income₹5.60B₹4.18B₹3.81B₹3.14B₹2.66B
Free cash flown/a₹3.51B₹652M₹473M₹1.88B
Capital expendituren/a₹1.31B₹1.73B₹2.09B₹536M
Total debt₹4.65B₹3.43B₹3.22B₹2.44B₹1.23B

Quarterly statements and history in the cockpit →

Marksans Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-20%0%+20%3102104516DMRA140410PAHC002626002020CORONA141080226950298380NANO300181600572068760688293MNKDMARKSANS.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Marksans Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×4516PAHC002626002020CORONA688293MNKDMARKSANS.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Marksans Pharma is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%4516PAHC002020CORONA300181603235068760688293MARKSANS.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Marksans Pharma is the large dot.

Marksans Pharma competitors and peer comparison

Head to head with its named competitors (MARKSANS.NS vs AUROPHARMA.NS vs CAPLIPOINT.NS vs LUPIN.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Marksans Pharma MARKSANS.NS$1.43B+36%+24%20%23.2×31.0%
Aurobindo Pharma AUROPHARMA.NS$11.0B+19%+14%15%22.3×21.1%
Caplin Point Laboratories CAPLIPOINT.NS$1.70B+2%+17%31%21.4×24.3%
Lupin LUPIN.NS$9.67B-14%+24%24%21.0×8.8%

How Marksans Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Marksans Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureMARKSANS.NSPeer medianRank in peer set
1-month return-2.8%-3.7%10th highest of 20
6-month return+35.5%-14.6%2nd highest of 20
Distance from 52-week high-16.1%-40.8%highest of 20
Revenue growth (TTM)+24.2%+11.3%4th highest of 19
Operating margin20.0%10.2%2nd highest of 19
Forward P/E23.2×16.0×5th most expensive of 10
Growth the price implies (Req g, 7 yrs)31.0%-4.9%2nd most demanding of 10
Growth delivered (Del g)+16.6%+12.7%5th highest of 10
Hurdle (Req g minus delivered)+14.5 pp-8.0 pp2nd most demanding of 10
ROIC minus cost of capital-0.5 pp-1.8 pp10th highest of 20
EV / EBITDA16.2×13.7×3rd cheapest of 5
Net debt / EBITDA-0.8×0.3×2nd least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Marksans Pharma MARKSANS.NSIndia$1.43B+36%+24%20%23.2×31.0%+16.6%
Voronoi 310210.KSSouth Korea$1.43B-62%-100%-438,152%n/an/an/a
Nippon Shinyaku 4516.TJapan$1.42B-20%+18%18%7.9×-18.1%+7.0%
Damora Therapeutics DMRAUnited States$1.42B-5%n/an/an/an/an/a
Mezzion Pharma 140410.KSSouth Korea$1.43B-15%+13%-211%n/an/an/a
Phibro Animal Health PAHCUnited States$1.44B+5%+10%13%9.9×-6.4%+12.7%
Xiamen Kingdomway 002626.SZChina$1.45B-3%-3%11%27.2×n/an/a
Zhejiang Jingxin Pharmaceutical 002020.SZChina$1.39B-19%+1%19%12.1×-9.6%+4.6%
Corona Remedies CORONA.NSIndia$1.48B+27%+17%18%58.9×36.3%+16.6%
LigaChem Biosciences 141080.KSSouth Korea$1.48B-72%-55%-324%n/an/an/a
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%n/an/an/a
ABL Bio 298380.KSSouth Korea$1.51B-71%-53%-201%n/an/an/a
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%n/an/an/a
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%13.0×3.9%+22.8%
JiangXi Tianxin Pharmaceutical 603235.SSChina$1.52B-9%+16%24%n/a-4.9%+0.2%
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%16.0×-6.1%+1.9%
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%n/an/an/a
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%n/a10.2%+18.1%
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%48.6×25.9%+23.1%
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
MannKind MNKDUnited States$1.31B+25%+32%-2%174.4×n/an/a

Questions

Who are Marksans Pharma's main competitors?
Named competitors: Aurobindo Pharma (AUROPHARMA.NS), Caplin Point Laboratories (CAPLIPOINT.NS), Lupin (LUPIN.NS). The cockpit's measured peer set (industry) also includes Voronoi (310210.KS), Nippon Shinyaku (4516.T), Damora Therapeutics (DMRA), Mezzion Pharma (140410.KS), Phibro Animal Health (PAHC), Xiamen Kingdomway (002626.SZ).
Is Marksans Pharma expensive compared with its peers?
On forward p/e it trades at 23.2× against a peer median of 16.0×, 5th most expensive of 10 in its peer set. For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Marksans Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +35.5% against -14.6% for the median peer; over one year +49.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.